Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aims: To compare the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 ( GLP ‐1) analogues between Asians and non‐Asians with type 2 diabetes. Methods: We searched randomized controlled trials from MEDLINE , EMBASE , LILACS , CENTRAL and ClinicalTrials.gov . Studies described in English were included if the treatment duration was 12 weeks or more, information about ethnicity and baseline HbA1c values were available and a GLP ‐1 analogue was compared with a placebo. For the ethnic comparison, we divided the studies into Asian‐dominant studies (≥50% Asian participants) and non‐Asian‐dominant studies (<50% Asian participants). Results: Among the 837 searched studies, 15 trials were included for the meta‐analysis. The weighted mean difference of HbA1c with GLP ‐1 analogues was −1.16% [95% confidence interval ( CI ) −1.48, −0.85] in the Asian‐dominant studies and −0.83% (95% CI −0.97, −0.70) in the non‐Asian‐dominant studies. The between‐group difference was −0.32% (95% CI −0.64, −0.01; p = 0.04). The relative risk ( RR ) with 95% CIs for achieving the target HbA1c ≤7.0% tended to be greater in the Asian‐dominant studies [ RR 5.7 (3.8, 8.7)] than in the non‐Asian‐dominant studies [ RR 2.8 (2.4, 3.3)]. Body weight changes were similar between the two groups. Hypoglycaemia tended to be more common in Asian‐dominant studies ( RR 2.8 [2.3, 3.5]) than in non‐Asian‐dominant studies ( RR 1.5 [1.2, 1.8]), but severe hypoglycaemia was very rare in both groups. Conclusion: GLP ‐1 analogues lower HbA1c more in Asian‐dominant studies than in non‐Asian‐dominant studies. Further studies are warranted to explore the potential mechanisms of the ethnic difference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 3×
“[15,16,19,21,22,25,38,39,41,43,44] compared with the Asiandominant studies [n = 3; −0.”
BackgroundResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 3×
“Importantly, the GLP-1 analogue was added on top of the sulfonylurea treatment in all Asian-dominant studies [17,18,35,42] and 2 out of 11 studies of non-Asian-dominant studies [15,19].”
BackgroundResultNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“Because the definition of nausea is somewhat vague and the frequency of nausea was sometimes reported to be highly variable even when using the same GLP-1 analogue [50,51], caution is warranted in the interpretation of the results.”
ResultZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Cited by
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3361 · Cited by 539
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Yabe, D., Seino, Y., Fukushima, M., & Seino, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0602-9 · Cited by 328
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
Metadata
- Authors
- Kim, Y. G., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-04-15
- Volume
- 16
- Issue
- 10
- Pages
- 900-909
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2034667874
- Cited by
- 171
- References
- 18
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/dom.12293
- The paper
- Kim, Y. G., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M. (2014). Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.